Welcome to industryreportstore.com

Need help? +44(0)20 7936 6830

Pancreatic Cancer - Pipeline Review, H2 2016

By: Global Markets Direct
, Published: Dec-2016
, Product code: GMDHC8862IDB
Key Insights
    • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
    • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Companies mentioned in this product:

3M Drug Delivery Systems 4SC AG AB Science SA AbbVie Inc AbGenomics International Inc Ability Pharmaceuticals SL Acetylon Pharmaceuticals Inc Adamed Sp z oo Adamis Pharmaceuticals Corp Aduro BioTech Inc Advantagene Inc Advaxis Inc Agenus Inc AGV Discovery SAS AIMM Therapeutics BV Alchemia Ltd Alissa Pharma Allinky Biopharma Almac Discovery Ltd Altor BioScience Corp Ambrx Inc amcure GmbH American Gene Technologies International Inc Amgen Inc Anavex Life Sciences Corp Andarix Pharmaceuticals Inc ANP Technologies Inc AntiCancer Inc APEIRON Biologics AG Aphios Corp APIM Therapeutics AS Apogenix GmbH Aposense Ltd ARMO Biosciences Inc ArQule Inc Array BioPharma Inc Astellas Pharma Inc AstraZeneca Plc ATLAB Pharma SAS Aurigene Discovery Technologies Ltd AVEO Pharmaceuticals Inc Axcentua Pharmaceuticals AB Azaya Therapeutics Inc Basilea Pharmaceutica Ltd Bavarian Nordic A/S Bayer AG BeiGene Ltd Bellicum Pharmaceuticals Inc Berg LLC BerGenBio AS Betta Pharmaceuticals Co Ltd Bexion Pharmaceuticals LLC BeyondSpring Pharmaceuticals Inc Bio-Path Holdings Inc BioLineRx Ltd Biomar Microbial Technologies Biomunex Pharmaceuticals Bioncotech Therapeutics SL Bionomics Ltd BioNTech AG BiOrion Technologies BV Biotest AG Biouniversa srl BLR Bio LLC Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Cadila Pharmaceuticals Ltd Calithera Biosciences Inc Cantargia AB Cascadian Therapeutics Inc Cavion LLC Celgene Corp Cellceutix Corp Cellular Biomedicine Group Inc Celprogen Inc Celyad SA Centrose LLC Ceronco Biosciences ChemoCentryx Inc Chiome Bioscience Inc Chugai Pharmaceutical Co Ltd Clovis Oncology Inc COARE Biotechnology Inc Concordia International Corp Confluence Life Sciences Inc Cornerstone Pharmaceuticals Inc Critical Outcome Technologies Inc CrystalGenomics Inc CTI BioPharma Corp Cyclacel Pharmaceuticals Inc CytomX Therapeutics Inc CytRx Corp CyTuVax BV Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd DEKK-TEC Inc Diffusion Pharmaceuticals Inc Eisai Co Ltd Eleison Pharmaceuticals LLC Eli Lilly and Company Endor Nanotechnologies SL Ensemble Therapeutics Corp Ensol Biosciences Inc Erytech Pharma SA Esperance Pharmaceuticals Inc Etubics Corp Exelixis Inc F. Hoffmann-La Roche Ltd FibroGen Inc Five Prime Therapeutics Inc Fountain Biopharma Inc Fujifilm Corp Fusion Antibodies Ltd Galena Biopharma Inc GamaMabs Pharma SA Ganymed Pharmaceuticals AG Geistlich Pharma AG Genelux Corp Genentech Inc Genisphere Inc Genmab A/S Gilead Sciences Inc GlaxoSmithKline Plc Globeimmune Inc GlycoMimetics Inc Golden Biotechnology Corp GW Pharmaceuticals Plc Halozyme Therapeutics Inc HEC Pharm Co Ltd Helix BioPharma Corp Horizon Pharma Plc iCeutica Inc Igenica Biotherapeutics Inc Ignyta Inc Immodulon Therapeutics Ltd Immune Pharmaceuticals Inc Immune System Key Ltd Immune Therapeutics Inc Immunomedics Inc Immunotope Inc Immunovo BV Immupharma Plc Incuron LLC Incyte Corp Inflection Biosciences Ltd Innopharmax Inc Inovio Pharmaceuticals Inc InteRNA Technologies BV Intica Biomedical Inc Inventiva InvivoGen Therapeutics Io Therapeutics Inc ISU ABXIS Co Ltd Jasco Pharmaceuticals LLC Jiangsu Hengrui Medicine Co Ltd Johnson & Johnson Juno Therapeutics Inc Kadmon Corp LLC Kancera AB Karcinolys SAS Karyopharm Therapeutics Inc Keystone Nano Inc Komipharm International Co Ltd Kura Oncology Inc Kyowa Hakko Kirin Co Ltd Lead Discovery Center GmbH Lion Biotechnologies Inc Lymphocyte Activation Technologies SA MabVax Therapeutics Holdings Inc MacroGenics Inc Mateon Therapeutics Inc MaxiVAX SA Meabco A/S Mebiopharm Co Ltd MediaPharma srl Medicenna Therapeutics Inc MedImmune LLC Medisyn Technologies Inc Medivation Inc Merck & Co Inc Merck KGaA Merrimack Pharmaceuticals Inc Merus NV Moleculin Biotech Inc MolMed SpA Monopar Therapeutics LLC Morphotek Inc Multimmune GmbH NanoCarrier Co Ltd NantKwest Inc Nascent Biotech Inc Natco Pharma Ltd NatureWise Biotech & Medicals Corp Nerviano Medical Sciences Srl NewLink Genetics Corp NormOxys Inc Northwest Biotherapeutics Inc Novartis AG Noxxon Pharma AG NuCana BioMed Ltd Omeros Corp Omnitura Therapeutics Inc Oncodesign SA Oncology Research International Ltd Oncolytics Biotech Inc Oncomatryx Biopharma SL OncoMed Pharmaceuticals Inc OncoTherapy Science Inc Oncovir Inc Ono Pharmaceutical Co Ltd Onxeo SA Opsona Therapeutics Ltd Optimum Therapeutics LLC Orega Biotech SAS Oribase Pharma Oryx GmbH & Co KG Oscotec Inc Patrys Ltd Pfizer Inc Pharma Two B Ltd PharmAbcine Inc Pharmacyclics Inc PharmaCyte Biotech Inc Pharmedartis GmbH Phoenix Biotechnology Inc Pique Therapeutics Plexxikon Inc Polaris Pharmaceuticals Inc Precision Biologics Inc Prima BioMed Ltd ProNAi Therapeutics Inc Propanc Health Group Corp Provectus Biopharmaceuticals Inc Quest PharmaTech Inc Quimatryx SL RedHill Biopharma Ltd Redx Pharma Plc RESprotect GmbH Rexahn Pharmaceuticals Inc Rhizen Pharmaceuticals SA Rigontec GmbH Samumed LLC Sanofi Sapience Therapeutics Inc Sareum Holdings Plc SATT North SAS Savoy Pharmaceuticals Inc SignPath Pharma Inc Silence Therapeutics Plc Sillajen Biotherapeutics Soluventis GmbH Soricimed Biopharma Inc Spotlight Innovation Inc
Table of Contents
Table of Contents
Table of Contents 2
Introduction 14
Pancreatic Cancer Overview 15
Therapeutics Development 16
Pancreatic Cancer - Therapeutics under Development by Companies 18
Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 45
Pancreatic Cancer - Pipeline Products Glance 49
Pancreatic Cancer - Products under Development by Companies 53
Pancreatic Cancer - Products under Investigation by Universities/Institutes 88
Pancreatic Cancer - Companies Involved in Therapeutics Development 93
Pancreatic Cancer - Therapeutics Assessment 397
Drug Profiles 478
Pancreatic Cancer - Dormant Projects 1889
Pancreatic Cancer - Discontinued Products 1922
Pancreatic Cancer - Product Development Milestones 1929
Appendix 1942
Tables and Figures
List of Tables
Number of Products under Development for Pancreatic Cancer, H2 2016 79
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80
Number of Products under Development by Companies, H2 2016 82
Number of Products under Development by Companies, H2 2016 (Contd..1) 83
Number of Products under Development by Companies, H2 2016 (Contd..2) 84
Number of Products under Development by Companies, H2 2016 (Contd..3) 85
Number of Products under Development by Companies, H2 2016 (Contd..4) 86
Number of Products under Development by Companies, H2 2016 (Contd..5) 87
Number of Products under Development by Companies, H2 2016 (Contd..6) 88
Number of Products under Development by Companies, H2 2016 (Contd..7) 89
Number of Products under Development by Companies, H2 2016 (Contd..8) 90
Number of Products under Development by Companies, H2 2016 (Contd..9) 91
Number of Products under Development by Companies, H2 2016 (Contd..10) 92
Number of Products under Development by Companies, H2 2016 (Contd..11) 93
Number of Products under Development by Companies, H2 2016 (Contd..12) 94
Number of Products under Development by Companies, H2 2016 (Contd..13) 95
Number of Products under Development by Companies, H2 2016 (Contd..14) 96
Number of Products under Development by Companies, H2 2016 (Contd..15) 97
Number of Products under Development by Companies, H2 2016 (Contd..16) 98
Number of Products under Development by Companies, H2 2016 (Contd..17) 99
Number of Products under Development by Companies, H2 2016 (Contd..18) 100
Number of Products under Development by Companies, H2 2016 (Contd..19) 101
Number of Products under Development by Companies, H2 2016 (Contd..20) 102
Number of Products under Development by Companies, H2 2016 (Contd..21) 103
Number of Products under Development by Companies, H2 2016 (Contd..22) 104
Number of Products under Development by Companies, H2 2016 (Contd..23) 105
Number of Products under Development by Companies, H2 2016 (Contd..24) 106
Number of Products under Development by Companies, H2 2016 (Contd..25) 107
Number of Products under Investigation by Universities/Institutes, H2 2016 108
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 109
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 110
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 111
Comparative Analysis by Late Stage Development, H2 2016 112
Comparative Analysis by Clinical Stage Development, H2 2016 113
Comparative Analysis by Early Stage Development, H2 2016 114
Comparative Analysis by Unknown Stage Development, H2 2016 115
Products under Development by Companies, H2 2016 116
Products under Development by Companies, H2 2016 (Contd..1) 117
Products under Development by Companies, H2 2016 (Contd..2) 118
Products under Development by Companies, H2 2016 (Contd..3) 119
Products under Development by Companies, H2 2016 (Contd..4) 120
Products under Development by Companies, H2 2016 (Contd..5) 121
Products under Development by Companies, H2 2016 (Contd..6) 122
Products under Development by Companies, H2 2016 (Contd..7) 123
Products under Development by Companies, H2 2016 (Contd..8) 124
Products under Development by Companies, H2 2016 (Contd..9) 125
Products under Development by Companies, H2 2016 (Contd..10) 126
Products under Development by Companies, H2 2016 (Contd..11) 127
Products under Development by Companies, H2 2016 (Contd..12) 128
Products under Development by Companies, H2 2016 (Contd..13) 129
Products under Development by Companies, H2 2016 (Contd..14) 130
Products under Development by Companies, H2 2016 (Contd..15) 131
Products under Development by Companies, H2 2016 (Contd..16) 132
Products under Development by Companies, H2 2016 (Contd..17) 133
Products under Development by Companies, H2 2016 (Contd..18) 134
Products under Development by Companies, H2 2016 (Contd..19) 135
Products under Development by Companies, H2 2016 (Contd..20) 136
Products under Development by Companies, H2 2016 (Contd..21) 137
Products under Development by Companies, H2 2016 (Contd..22) 138
Products under Development by Companies, H2 2016 (Contd..23) 139
Products under Development by Companies, H2 2016 (Contd..24) 140
Products under Development by Companies, H2 2016 (Contd..25) 141
Products under Development by Companies, H2 2016 (Contd..26) 142
Products under Development by Companies, H2 2016 (Contd..27) 143
Products under Development by Companies, H2 2016 (Contd..28) 144
Products under Development by Companies, H2 2016 (Contd..29) 145
Products under Development by Companies, H2 2016 (Contd..30) 146
Products under Development by Companies, H2 2016 (Contd..31) 147
Products under Development by Companies, H2 2016 (Contd..32) 148
Products under Development by Companies, H2 2016 (Contd..33) 149
Products under Development by Companies, H2 2016 (Contd..34) 150
Products under Investigation by Universities/Institutes, H2 2016 151
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 152
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 153
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 154
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 155
Pancreatic Cancer - Pipeline by 3M Drug Delivery Systems, H2 2016 156
Pancreatic Cancer - Pipeline by 4SC AG, H2 2016 157
Pancreatic Cancer - Pipeline by AB Science SA, H2 2016 158
Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016 159
Pancreatic Cancer - Pipeline by AbGenomics International Inc, H2 2016 160
Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016 161
Pancreatic Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 162
Pancreatic Cancer - Pipeline by Adamed Sp z oo, H2 2016 163
Pancreatic Cancer - Pipeline by Adamis Pharmaceuticals Corp, H2 2016 164
Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H2 2016 165
Pancreatic Cancer - Pipeline by Advantagene Inc, H2 2016 166
Pancreatic Cancer - Pipeline by Advaxis Inc, H2 2016 167
Pancreatic Cancer - Pipeline by Agenus Inc, H2 2016 168
Pancreatic Cancer - Pipeline by AGV Discovery SAS, H2 2016 169
Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H2 2016 170
Pancreatic Cancer - Pipeline by Alchemia Ltd, H2 2016 171
Pancreatic Cancer - Pipeline by Alissa Pharma, H2 2016 172
Pancreatic Cancer - Pipeline by Allinky Biopharma, H2 2016 173
Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H2 2016 174
Pancreatic Cancer - Pipeline by Altor BioScience Corp, H2 2016 175
Pancreatic Cancer - Pipeline by Ambrx Inc, H2 2016 176
Pancreatic Cancer - Pipeline by amcure GmbH, H2 2016 177
Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H2 2016 178
Pancreatic Cancer - Pipeline by Amgen Inc, H2 2016 179
Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 180
Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016 181
Pancreatic Cancer - Pipeline by ANP Technologies Inc, H2 2016 182
Pancreatic Cancer - Pipeline by AntiCancer Inc, H2 2016 183
Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H2 2016 184
Pancreatic Cancer - Pipeline by Aphios Corp, H2 2016 185
Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H2 2016 186
Pancreatic Cancer - Pipeline by Apogenix GmbH, H2 2016 187
Pancreatic Cancer - Pipeline by Aposense Ltd, H2 2016 188
Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 189
Pancreatic Cancer - Pipeline by ArQule Inc, H2 2016 190
Pancreatic Cancer - Pipeline by Array BioPharma Inc, H2 2016 191
Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H2 2016 192
Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016 193
Pancreatic Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 194
Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 195
Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 196
Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016 197
Pancreatic Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 198
Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 199
Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 200
Pancreatic Cancer - Pipeline by Bayer AG, H2 2016 201
Pancreatic Cancer - Pipeline by BeiGene Ltd, H2 2016 202
Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 203
Pancreatic Cancer - Pipeline by Berg LLC, H2 2016 204
Pancreatic Cancer - Pipeline by BerGenBio AS, H2 2016 205
Pancreatic Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016 206
Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H2 2016 207
Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016 208
Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 209
Pancreatic Cancer - Pipeline by BioLineRx Ltd, H2 2016 210
Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H2 2016 211
Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H2 2016 212
Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H2 2016 213
Pancreatic Cancer - Pipeline by Bionomics Ltd, H2 2016 214
Pancreatic Cancer - Pipeline by BioNTech AG, H2 2016 215
Pancreatic Cancer - Pipeline by BiOrion Technologies BV, H2 2016 216
Pancreatic Cancer - Pipeline by Biotest AG, H2 2016 217
Pancreatic Cancer - Pipeline by Biouniversa srl, H2 2016 218
Pancreatic Cancer - Pipeline by BLR Bio LLC, H2 2016 219
Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 220
Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H2 2016 221
Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 222
Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H2 2016 223
Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 224
Pancreatic Cancer - Pipeline by Cantargia AB, H2 2016 225
Pancreatic Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2016 226
Pancreatic Cancer - Pipeline by Cavion LLC, H2 2016 227
Pancreatic Cancer - Pipeline by Celgene Corp, H2 2016 228
Pancreatic Cancer - Pipeline by Cellceutix Corp, H2 2016 229
Pancreatic Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 230
Pancreatic Cancer - Pipeline by Celprogen Inc, H2 2016 231
Pancreatic Cancer - Pipeline by Celyad SA, H2 2016 232
Pancreatic Cancer - Pipeline by Centrose LLC, H2 2016 233
Pancreatic Cancer - Pipeline by Ceronco Biosciences, H2 2016 234
Pancreatic Cancer - Pipeline by ChemoCentryx Inc, H2 2016 235
Pancreatic Cancer - Pipeline by Chiome Bioscience Inc, H2 2016 236
Pancreatic Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 237
Pancreatic Cancer - Pipeline by Clovis Oncology Inc, H2 2016 238
Pancreatic Cancer - Pipeline by COARE Biotechnology Inc, H2 2016 239
Pancreatic Cancer - Pipeline by Concordia International Corp, H2 2016 240
Pancreatic Cancer - Pipeline by Confluence Life Sciences Inc, H2 2016 241
Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 242
Pancreatic Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016 243
Pancreatic Cancer - Pipeline by CrystalGenomics Inc, H2 2016 244
Pancreatic Cancer - Pipeline by CTI BioPharma Corp, H2 2016 245
Pancreatic Cancer - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 246
Pancreatic Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016 247

List of Figures
Number of Products under Development for Pancreatic Cancer, H2 2016 79
Number of Products under Development for Pancreatic Cancer - Comparative Analysis, H2 2016 80
Number of Products under Development by Companies, H2 2016 81
Number of Products under Investigation by Universities/Institutes, H2 2016 108
Comparative Analysis by Late Stage Development, H2 2016 112
Comparative Analysis by Clinical Stage Development, H2 2016 113
Comparative Analysis by Early Stage Products, H2 2016 114
Assessment by Monotherapy Products, H2 2016 460
Assessment by Combination Products, H2 2016 461
Number of Products by Top 10 Targets, H2 2016 462
Number of Products by Stage and Top 10 Targets, H2 2016 462
Number of Products by Top 10 Mechanism of Actions, H2 2016 504
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 504
Number of Products by Top 10 Routes of Administration, H2 2016 537
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 537
Number of Products by Top 10 Molecule Types, H2 2016 539
Number of Products by Stage and Top 10 Molecule Types, H2 2016 539
Sample Pages

Request Sample Pages

Pancreatic Cancer - Pipeline Review, H2 2016
By: Global Markets Direct
Published: Dec 2016
Contact Details


Download Brochure

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 15, 106, 112, 1, 3, 249, 38 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 18, 7, 50 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Synopsis

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons To Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Quick Overview

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Pipeline Review, H2 2016, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

More information about Pancreatic Cancer - Pipeline Review, H2 2016

For more information on this report or to speak to one of our experts

Call us on +44(0)20 7936 6830 or Email us

mail

For more information
on this report or to speak to one of our experts

Email us or call us on
+44(0)20 7936 6830

Purchase

Site License - This allows anybody within a business at the same site to view the report.

Single-user - This allows only one person to view the report.

Enterprise License -  This allows anybody globally within the organisation to view the report.

Preview Report

For a free preview of this report please complete our simple form.

Request
mail

Read our latest
Industry Insights Blog
and stay informed